Impact of postoperative intravaginal brachytherapy on survival for patients with intermediate-risk cervical cancer at National Cancer Institute (NCI), Egypt

被引:2
|
作者
Mahmoud, Mohamed [1 ]
Abdelgeleel, Shaimaa [2 ]
Mahmoud, Ahmed M. [3 ]
机构
[1] Cairo Univ, Dept Radiat Oncol, NCI, Giza, Egypt
[2] Cairo Univ, NCI, Epidemiol & Canc Biostat Dept, Giza, Egypt
[3] Cairo Univ, NCI, Surg Oncol Dept, Giza, Egypt
关键词
brachytherapy; cervical cancer; survival;
D O I
10.1017/S1460396918000018
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: Cervical cancer is considered to be the fourth most frequent cancer among women. Postoperative treatment is indicated depending up on surgical findings and disease stage. Objective: The objective of this study was to assess the long-term postoperative outcomes of cervical cancer patients with intermediate risk factors who have received pelvic external beam radiotherapy with or without vaginal brachytherapy, and treatment-related toxicities. Patients and methods: In this retrospective study, the records were collected for all patients with cervical cancer who received postoperative radiotherapy at the National Cancer Institute between the years 2008 and 2013. The end points of the study were local control, progression-free survival, overall survival (OS) and delayed complications. Results: Out of 248 patients, the median age of patients who did not receive brachytherapy was 53 years and the median age of patients who received brachytherapy was 52 years. A statistically significant difference was found in OS, progression-free survival and recurrence-free survival for those who received brachytherapy, with a p value <0.001, 0.01 and 0.004, respectively. Conclusion: The addition of brachytherapy to postoperative external beam radiotherapy improves OS, progression-free survival and local control for patients with intermediate-risk cervical cancer.
引用
收藏
页码:332 / 336
页数:5
相关论文
共 50 条
  • [31] Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer
    Takamoto, Atsushi
    Tanimoto, Ryuta
    Bekku, Kensuke
    Araki, Motoo
    Sadahira, Takuya
    Wada, Koichiro
    Ebara, Shin
    Katayama, Norihisa
    Yanai, Hiroyuki
    Nasu, Yasutomo
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (05) : 507 - 512
  • [32] A comparison of disease recurrence between robotic versus laparotomy approach in patients with intermediate-risk endometrial cancer
    Song, Jiheon
    Le, Tien
    Hopkins, Laura
    Fung-Kee-Fung, Michael
    Lupe, Krystine
    Gaudet, Marc
    Choan, E.
    Samant, Rajiv
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (02) : 160 - 166
  • [33] Postoperative treatment of intermediate-risk early stage cervical cancer: results of a survey from the Gynecology Study Group in the AIRO Gyn and MITO Groups
    Perrucci, Elisabetta
    Cerrotta, Annamaria
    Macchia, Gabriella
    Augurio, Antonietta
    Campitelli, Maura
    De Sanctis, Vitaliana
    Lazzari, Roberta
    Magri, Elena
    Marsella, Anna Rita
    Meregalli, Sofia
    Tamburo, Marinella
    Ferrandina, Gabriella
    Aristei, Cynthia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 174
  • [34] Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy
    Rijkmans, E. C.
    Nout, R. A.
    Rutten, I. H. H. M.
    Ketelaars, M.
    Neelis, K. J.
    Laman, M. S.
    Coen, V. L. M. A.
    Gaarenstroom, K. N.
    Kroep, J. R.
    Creutzberg, C. L.
    GYNECOLOGIC ONCOLOGY, 2014, 135 (02) : 231 - 238
  • [35] A novel predictor for the use of concurrent chemotherapy in early-stage cervical cancer with intermediate-risk factors
    Fu, Chunli
    Wang, Cong
    Qian, Qiuhong
    Zhang, Youzhong
    Ma, Changdong
    Miao, Li
    Zhang, Guangyu
    GYNECOLOGIC ONCOLOGY REPORTS, 2023, 48
  • [36] Survival of patients with squamous cell cervical cancer and adenocarcinoma treated in the National Cancer Institute. 2009-2013
    Villalobos C, Michael
    Wendling C, Carolina
    Sierra H, Claudia
    Valencia C, Oscar
    Carcamo, Marcela, I
    Gayan P, Patricio
    GACETA MEXICANA DE ONCOLOGIA, 2016, 15 (05): : 263 - 267
  • [37] Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study
    S Y Ryu
    M H Kim
    B H Nam
    T S Lee
    E S Song
    C Y Park
    J W Kim
    Y B Kim
    H S Ryu
    S Y Park
    K T Kim
    C H Cho
    C Lee
    S M Kim
    B G Kim
    D S Bae
    Y T Kim
    J-H Nam
    British Journal of Cancer, 2014, 110 : 278 - 285
  • [38] Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study
    Ryu, S. Y.
    Kim, M. H.
    Nam, B. H.
    Lee, T. S.
    Song, E. S.
    Park, C. Y.
    Kim, J. W.
    Kim, Y. B.
    Ryu, H. S.
    Park, S. Y.
    Kim, K. T.
    Cho, C. H.
    Lee, C.
    Kim, S. M.
    Kim, B. G.
    Bae, D. S.
    Kim, Y. T.
    Nam, J-H
    BRITISH JOURNAL OF CANCER, 2014, 110 (02) : 278 - 285
  • [39] Variable impact of intracavitary brachytherapy fractionation schedule on biologically effective dose to organs at risk in patients with cervical cancer
    Christensen, Eva N.
    Yu, Henry Z.
    Klopp, Ann H.
    Tsai, Jillian C.
    Lawyer, Ann A.
    Court, Laurence E.
    Eifel, Patricia J.
    BRACHYTHERAPY, 2014, 13 (03) : 240 - 249
  • [40] Higher caseload improves cervical cancer survival in patients treated with brachytherapy
    Moon-Sing Lee
    Shiang-Jiun Tsai
    Ching-Chih Lee
    Yu-Chieh Su
    Wen-Yen Chiou
    Hon-Yi Lin
    Shih-Kai Hung
    Radiation Oncology, 9